The cover for
issue 31
of
Oncotarget
features Figure 4, ”
Concentration dose-response curves of sirolimus effect [55 nM–1 nM] on the number of cells per surviving colony in U2OS cell line after 2 weeks exposure,
” by Vasuri, et al. which reported that the authors evaluated the long-term effects of sirolimus on three different cell in vitro models, cultured in physiological conditions mimicking sirolimus-eluted stent, in order to clarify the effectiveness of sirolimus in blocking cell proliferation and survival.
Three cell lines were selected and growth in 10 ml of Minimum Essential Medium for 5 weeks with serial dilutions of sirolimus.
The number of colonies and the number of cells per colony were counted.
As a result, the number of WPMY-1 surviving colonies increased in a dose-dependent manner when treated with sirolimus, while the number of U2OS colonies progressively decreased.
In conclusion sirolimus showed the well-known cytostatic effect, but with an effect on clonogenic potential different among the different cell types.
Dr. Gianandrea Pasquinelli from The Bologna University said, ”
Rapamycin
(sirolimus) is a widely used cytostatic drug blocking the cell cycle in the phase G1/S through the inhibition of the mammalian target of Rapamycin (mTOR) pathway, that has found several clinical applications, from immunosuppression in diabetes and organ transplantation to cancer therapy and drug-eluting stents (DES)
”
Beside to its cytostatic activity, sirolimus was also discovered to protect normal human oral keratinocytes from apoptosis by activating autophagy, and to act as a basal stem cell keratinocyte-protecting drug in irradiated mice.
The effect of sirolimus on mesenchymal cells is unknown, but it is an important issue, since mesenchymal cells such as myofibroblasts and cells promoting vascular calcification play an important role in atherogenesis and vascular restenosis.
Sirolimus seems to block the proliferation and the migration of vascular smooth muscle cells, but we lack information concerning the effects on other cells composing atherosclerotic plaques.
The aim of the present paper is to evaluate the long-term effects of sirolimus, rather than short-term cell survival, on three different cell in vitro models, cultured in Minimum Essential Medium, which simulates physiological conditions (w/o CO2 and glucose, in order to clarify the effectiveness of sirolimus in blocking cell proliferation and survival.
The Pasquinelli Research Team concluded in their
Oncotarget
Research Paper
that the plaque typology and the different cell composition of the plaque, e. g.,
the presence of inflammatory cells, angiogenesis, prevalence of fibrosis, presence of osteogenic progenitors, may influence the response to sirolimus.
“The presence of inflammatory cells, angiogenesis, prevalence of fibrosis, presence of osteogenic progenitors, may influence the response to sirolimus”
Moreover, it is known that the clonal capacity varies between cells and we should consider this matter when evaluating the effectiveness of eluted stent.
Finally, additional mechanisms can have a role, such as amitotic cell division.
These mechanisms were also observed in human atherogenesis and could be fundamental to evaluate the in vivo effect of sirolimus too.
###
Sign up for free Altmetric alerts about this article
DOI
–
https:/
/
doi.
org/
10.
18632/
oncotarget.
27554
Full text
–
https:/
/
www.
oncotarget.
com/
article/
27554/
text/
Correspondence to
– Gianandrea Pasquinelli –
gianandr.pasquinelli@unibo.it
Keywords
–
atherosclerosis
,
cell proliferation
,
sirolimus
,
stents
About Oncotarget
Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.
To learn more about Oncotarget, please visit
https:/
/
www.
oncotarget.
com
or connect with:
SoundCloud –
https:/
/
soundcloud.
com/
oncotarget
Facebook –
https:/
/
www.
facebook.
com/
Oncotarget/
Twitter –
https:/
/
twitter.
com/
oncotarget
LinkedIn –
https:/
/
www.
linkedin.
com/
company/
oncotarget
Pinterest –
https:/
/
www.
pinterest.
com/
oncotarget/
Reddit –
https:/
/
www.
reddit.
com/
user/
Oncotarget/
Oncotarget is published by Impact Journals, LLC please visit
http://www.
ImpactJournals.
com
or connect with
@ImpactJrnls
Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957×105
This part of information is sourced from https://www.eurekalert.org/pub_releases/2020-10/ijl-oss100820.php
